The FTSE Russell ESG Rating has placed us in the 99th percentile, ranking us among the top 1% of assessed companies globally

The U.S. FDA approval of our Rituximab biosimilar marks another important milestone for our growing biosimilars portfolio. It is a step forward in our capability to develop and manufacture complex biologic medicines for global markets.